SIRT1 and fatty liver disease: In conclusion, the present investigation has provided initial evidence that Que-metformin, an innovative combined therapeutic approach, can reduce hepatic steatosis in PA-induced HepG2 cells by stimulating autophagy through the cAMP/AMPK/SIRT1 pathway and diminishing inflammatory cytokines.